Singular Health Group co-founder Denning Chong will focus on sealing key deals for the company’s groundbreaking 3D technology in the lucrative United States healthcare sector after being confirmed as managing director and chief executive officer.
Mr Chong been leading the company in an interim capacity since former boss Thomas Hanley resigned in April. A major plank in his role is to orchestrate licence sales in US hospitals for Singular’s 3Dicom product that has been designed to deliver x-ray, MRI and CT scan images to patients, which they can then view and share via mobile phones.
Singular says it has developed its “3Dicom MD” and “3Dicom Patient” products to be sold in bundles to help improve patient education and communication.
Also the principal of James Chong Lawyers since 2004, Mr Chong has been involved in the early-stage funding and governance of Singular since its incorporation and has more recently overseen a cost-cutting strategy and consolidation of the company’s operations in the southern Perth suburb of Bibra Lake.
A major financial aspect of the Perth-based operation is a strategy aimed at realising significant vertical integration from medical imaging to 3D printing. That plan appears well-founded given the global 3D-printed prosthetics market is expected to grow by 7.7 per cent annually and reach $3.4 billion by 2030.
The Board is delighted to be confirming Denning’s appointment as CEO and Managing Director. Together with our team, Denning has moved very quickly to implement strong business development activities in our chosen markets and build a foundation for long-term shareholder value. Singular Health Group chairman Howard Digby
In July, Mr Chong oversaw the company’s execution of a master distribution agreement for its 3Dicom software in the US with Charlie Golf One (CG1) Solutions – a South Florida-based information technology firm owned and run by veterans and service-disabled veterans.
A month later, Singular also secured a binding commitment to raise up to $850,000 through the issue of fully-paid ordinary shares in the company to CG1 Ventures. Management said it would allow it greater flexibility to explore larger-scale opportunities in the US on the back of strong commercial and corporate interest in its 3Dicom software.
Founded in 2017, Singular is on a mission to optimise emerging technologies to enable a more personalised healthcare approach through solutions such as fully-immersive 3D medical imaging, medical artificial intelligence (AI) models, surgical design and advanced manufacturing of patient-specific medical devices.
The company’s 3Dicom software solutions that empower patients and practitioners to better visualise, communicate and understand medical imaging data have been cleared for diagnostic use by the US Food and Drug Administration.
Back in April, Singular also revealed that Sony Electronics was likely to “actively promote” its 3Dicom medical device (MD) as a complementary application for the global giant’s second-generation Spatial Reality Display.
So, it seems there is plenty for Mr Chong to sink his teeth into.
Is your ASX-listed company doing something interesting? Contact: office@bullsnbears.com.au